REGULATORY

Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds

By Ken Yoshino September 5, 2024
The Ministry of Health, Labor and Welfare (MHLW) will be embarking on a multi-year project for setting up a first-in-human (FIH) study scheme in Japan to address new modalities, looking to bring the system up and running in the fiscal…

To read the full story

Related Article

REGULATORY

By Tatsuya Otsuka

Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…

Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…

By Sakura Kono

Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…

By Philip Carrigan

In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…